Are Stem Cell-Based Therapies for Parkinson's Disease Ready for the Clinic in 2016?

Research output: Contribution to journal › Review › Research › peer-review

Standard

Are Stem Cell-Based Therapies for Parkinson's Disease Ready for the Clinic in 2016? / Barker, Roger A.; Parmar, Malin; Kirkeby, Agnete; Björklund, Anders; Thompson, Lachlan; Brundin, Patrik.

In: Journal of Parkinson's Disease, Vol. 6, No. 1, 30.03.2016, p. 57-63.

Research output: Contribution to journal › Review › Research › peer-review

Harvard

Barker, RA, Parmar, M, Kirkeby, A, Björklund, A, Thompson, L & Brundin, P 2016, 'Are Stem Cell-Based Therapies for Parkinson's Disease Ready for the Clinic in 2016?', Journal of Parkinson's Disease, vol. 6, no. 1, pp. 57-63. https://doi.org/10.3233/JPD-160798

APA

Barker, R. A., Parmar, M., Kirkeby, A., Björklund, A., Thompson, L., & Brundin, P. (2016). Are Stem Cell-Based Therapies for Parkinson's Disease Ready for the Clinic in 2016? Journal of Parkinson's Disease, 6(1), 57-63. https://doi.org/10.3233/JPD-160798

Vancouver

Barker RA, Parmar M, Kirkeby A, Björklund A, Thompson L, Brundin P. Are Stem Cell-Based Therapies for Parkinson's Disease Ready for the Clinic in 2016? Journal of Parkinson's Disease. 2016 Mar 30;6(1):57-63. https://doi.org/10.3233/JPD-160798

Author

Barker, Roger A. ; Parmar, Malin ; Kirkeby, Agnete ; Björklund, Anders ; Thompson, Lachlan ; Brundin, Patrik. / Are Stem Cell-Based Therapies for Parkinson's Disease Ready for the Clinic in 2016?. In: Journal of Parkinson's Disease. 2016 ; Vol. 6, No. 1. pp. 57-63.

Bibtex

@article{fb0414edd531498788fb524464be9938,
title = "Are Stem Cell-Based Therapies for Parkinson's Disease Ready for the Clinic in 2016?",
abstract = "Recent news of an impending clinical cell transplantation trial in Parkinson's disease using parthenogenetic stem cells as a source of donor tissue have raised hopes in the patient community and sparked discussion in the research community. Based on discussions held by a global collaborative initiative on translation of stem cell therapy in Parkinson's disease, we have identified a set of key questions that we believe should be addressed ahead of every clinical stem cell-based transplantation trial in this disorder. In this article, we first provide a short history of cell therapy in Parkinson's disease and briefly describe the current state-of-art regarding human stem cell-derived dopamine neurons for use in any patient trial. With this background information as a foundation, we then discuss each of the key questions in relation to the upcoming therapeutic trial and critically assess if the time is ripe for clinical translation of parthenogenetic stem cell technology in Parkinson's disease.",
author = "Barker, {Roger A.} and Malin Parmar and Agnete Kirkeby and Anders Bj{\"o}rklund and Lachlan Thompson and Patrik Brundin",
year = "2016",
month = mar,
day = "30",
doi = "10.3233/JPD-160798",
language = "English",
volume = "6",
pages = "57--63",
journal = "Journal of Parkinson's Disease",
issn = "1877-7171",
publisher = "I O S Press",
number = "1",

}

RIS

TY - JOUR

T1 - Are Stem Cell-Based Therapies for Parkinson's Disease Ready for the Clinic in 2016?

AU - Barker, Roger A.

AU - Parmar, Malin

AU - Kirkeby, Agnete

AU - Björklund, Anders

AU - Thompson, Lachlan

AU - Brundin, Patrik

PY - 2016/3/30

Y1 - 2016/3/30

N2 - Recent news of an impending clinical cell transplantation trial in Parkinson's disease using parthenogenetic stem cells as a source of donor tissue have raised hopes in the patient community and sparked discussion in the research community. Based on discussions held by a global collaborative initiative on translation of stem cell therapy in Parkinson's disease, we have identified a set of key questions that we believe should be addressed ahead of every clinical stem cell-based transplantation trial in this disorder. In this article, we first provide a short history of cell therapy in Parkinson's disease and briefly describe the current state-of-art regarding human stem cell-derived dopamine neurons for use in any patient trial. With this background information as a foundation, we then discuss each of the key questions in relation to the upcoming therapeutic trial and critically assess if the time is ripe for clinical translation of parthenogenetic stem cell technology in Parkinson's disease.

AB - Recent news of an impending clinical cell transplantation trial in Parkinson's disease using parthenogenetic stem cells as a source of donor tissue have raised hopes in the patient community and sparked discussion in the research community. Based on discussions held by a global collaborative initiative on translation of stem cell therapy in Parkinson's disease, we have identified a set of key questions that we believe should be addressed ahead of every clinical stem cell-based transplantation trial in this disorder. In this article, we first provide a short history of cell therapy in Parkinson's disease and briefly describe the current state-of-art regarding human stem cell-derived dopamine neurons for use in any patient trial. With this background information as a foundation, we then discuss each of the key questions in relation to the upcoming therapeutic trial and critically assess if the time is ripe for clinical translation of parthenogenetic stem cell technology in Parkinson's disease.

U2 - 10.3233/JPD-160798

DO - 10.3233/JPD-160798

M3 - Review

C2 - 27003785

AN - SCOPUS:84963773053

VL - 6

SP - 57

EP - 63

JO - Journal of Parkinson's Disease

JF - Journal of Parkinson's Disease

SN - 1877-7171

IS - 1

ER -

ID: 228505478